This is a working overview of amino acid substitution, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
As a final step, McMillan and Abelson prepared a much larger sample of bombarded uranium that had a prominent 23-minute half-life from 239U and demonstrated conclusively that the unknown 2.3-day half-life increased in strength in concert with a decrease in the 23-minute activity through the following reaction:
Fisher formulate a zinc insulin mixture at Connaught Laboratories in Toronto and license it to Novo 1936 Hagedorn discovers that adding protamine to insulin prolongs the duration of action of insulin 1946 Nordisk formulates Isophane porcine insulin aka Neutral Protamine Hagedorn or NPH insulin 1946 Nordisk crystallizes a protamine and insulin mixture 1950 Nordisk markets NPH insulin 1953 Novo formulates Lente porcine and bovine insulins by adding zinc for longer lasting insulin 1955 Frederick Sanger determines the amino acid sequence of insulin 1965 Synthesized by total synthesis by Wang Yinglai, Chen-Lu Tsou, et al. 1969 Dorothy Crowfoot Hodgkin characterizes and describes the crystal structure of insulin by X-ray crystallography 1973 Purified monocomponent (MC) insulin is introduced 1973 The US officially "standardized" insulin sold for human use in the US to U-100 (100 units per milliliter). Prior to that, insulin was sold in different strengths, including U-80 (80 units per milliliter) and U-40 formulations (40 units per milliliter), so the effort to "standardize" the potency aimed to reduce dosage errors and ease doctors' job of prescribing insulin for people. Other countries also followed suit.
Finding the structure of proteins is an important application of bioinformatics. The Critical Assessment of Protein Structure Prediction (CASP) is an open competition where worldwide research groups submit protein models for evaluating unknown protein models.
== The Holocaust == On 6 March 1943, Eva and her parents were transported to the Theresienstadt Ghetto in Terezín, where her father was separated from her and her mother. In Terezín, she worked in agriculture, so she was able to go into the ghetto and managed to make contact with her father. In December 1943, she and her mother were transferred to the Auschwitz concentration camp, where she stayed until June 1944. After six months of horrible conditions at Auschwitz, Eva and her mother were unexpectedly recognized as able to work and were relocated to the Dessauer Ufer camp of the Neuengamme concentration camp in Hamburg, where she experienced better conditions. Her final transport was without her mother to Bergen-Belsen concentration camp in April 1945, which was liberated the same month.
The major means of respiration in teleosts, as in most other fish, is the transfer of gases over the surface of the gills as water is drawn in through the mouth and pumped out through the gills. Apart from the swim bladder, which contains a small amount of air, the body does not have oxygen reserves, and respiration needs to be continuous over the fish's life. Some teleosts exploit habitats where the oxygen availability is low, such as stagnant water or wet mud; they have developed accessory tissues and organs to support gas exchange in these habitats. Several genera of teleosts have independently developed air-breathing capabilities, and some have become amphibious. Some combtooth blennies emerge to feed on land, and freshwater eels are able to absorb oxygen through damp skin. Mudskippers can remain out of water for considerable periods, exchanging gases through skin and mucous membranes in the mouth and pharynx. Swamp eels have similar well-vascularised mouth-linings, and can remain out of water for days and go into a resting state (aestivation) in mud. The anabantoids have developed an accessory breathing structure known as the labyrinth organ on the first gill arch and this is used for respiration in air, and airbreathing catfish have a similar suprabranchial organ. Certain other catfish, such as the Loricariidae, are able to respire through air held in their digestive tracts.
Sources: en.wikipedia.org
=== Other endocrine conditions === Endocrine diseases that may lead to ketoacidosis include severe forms of hypothyroidism, thyrotoxicosis and adrenal failure. In all cases, the hormone-sensitive lipase in cells is phosphorylated and over-active, resulting in unrestrained lipolysis. Ketonemia and even ketoacidosis may arise from endocrine (non-diabetic) conditions alone, but the combination of endocrine and diabetic ketoacidosis leads to an especially unfavourable prognosis.
In 1945, Yeshiva University President Samuel Belkin began planning a new medical school. Under his urging, Yeshiva's Board of Trustees negotiated with the New York State Board of Regents to expand the university's charter to grant MD degrees, finalized in December 1950. In 1951, physicist Albert Einstein wrote a letter to Belkin lauding the planned school, writing that it was "of the greatest importance to American Jewry" and would "welcome students of all creeds and races". He became an honorary chairman for the medical school campaign, alongside former First Lady Eleanor Roosevelt, New York Governor Thomas Dewey, and Richard Nixon. When approached, Einstein was initially reluctant to associate his name with the school—he had recently refused to lend his name to Brandeis University and had declined to become the second president of Israel—and instead suggested that it be named for the Jewish physician Maimonides. Two years later, at an event marking his 74th birthday, March 14, 1953, Einstein agreed to lend his name to the medical school. At the gathering—his only public appearance in 22 years at the Institute for Advanced Study—Einstein told The New York Times that "physics has favored medicine by giving civilized man confidence in the scientific method." In 1954, the college sponsored the awarding of that year's Albert Einstein Award to physicist Richard Feynman and, on his 75th birthday, gifted Einstein a Festschrift with contributions from ten Nobel laureates, Israeli Prime Minister Moshe Sharett, and President Harry S. Truman, among others.
Perfluoroaromatic compounds can be manufactured via the Fowler process, like fluoroalkanes, but the conditions must be adjusted to prevent full fluorination. They can also be made by heating the corresponding perchloroaromatic compound with potassium fluoride at high temperature (typically 500 °C), during which the chlorine atoms are replaced by fluorine atoms. A third route is defluorination of the fluoroalkane; for example, octafluorotoluene can be made from perfluoromethylcyclohexane by heating to 500 °C with a nickel or iron catalyst. Perfluoroaromatic compounds are relatively volatile for their molecular weight, with melting and boiling points similar to the corresponding aromatic compound, as the table below shows. They have high density and are non-flammable. For the most part, they are colorless liquids. Unlike the perfluoralkanes, they tend to be miscible with common solvents.
=== Regulation === Translation is one of the key energy consumers in cells, hence it is strictly regulated. Numerous mechanisms have evolved that control and regulate translation in eukaryotes as well as prokaryotes. Regulation of translation can impact the global rate of protein synthesis which is closely coupled to the metabolic and proliferative state of a cell. To study this process, scientists have used a wide variety of methods such as structural biology, analytical chemistry (mass-spectrometry based), imaging of reporter mRNA translation (in which the translation of a mRNA is linked to an output, such as luminescence or fluorescence), detecting it via radioactive amino acid incorporation, and next-generation sequencing based methods. Other methods such as toeprinting assay can also be used to determine the location of ribosomes of a particular mRNA in vitro, and footprints of other proteins regulating translation. To delve deeper into this intricate process, scientists typically use a technique known as ribosome profiling. This method enables researchers to take a snapshot of the translatome, showing which parts of the mRNA are being translated into proteins by ribosomes at a given time. Ribosome profiling provides valuable insights into translation dynamics, revealing the complex interplay between gene sequence, mRNA structure, and translation regulation. Expanding on this concept, single-cell ribosome profiling, is a technique that allows the study of the translation process at the resolution of individual cells.
Sources: en.wikipedia.org
== Mechanism of action == Avalglucosidase alfa is composed of the human GAA enzyme that is conjugated with a couple of bis-mannose-6-phosphate (bis-M6P) tetra-mannose glycans. The bis-MGP of avalglucosidase alpha binds to the cation-independent mannose-6-phosphate receptor which is located on the skeletal muscles. Once the molecule binds to the receptor, the drug enters the cell. The drug then enters the lysosomes of the cell. Within the lysosome of the cell, the drugs undergoes cleavage proteolytically and then acts as an enzyme.
=== Mesenchymal stromal cells (MSCs) === MSCs, when transfused immediately within a few hours post-thawing, may show reduced function or show decreased efficacy in treating diseases as compared to those MSCs which are in log phase of cell growth (fresh). As a result, cryopreserved MSCs should be brought back into the log phase of cell growth in in vitro culture before these are administered for clinical trials or experimental therapies. Re-culturing of MSCs will help in recovering from the shock the cells get during freezing and thawing. Various clinical trials on MSCs have failed which used cryopreserved products immediately post-thaw as compared to those clinical trials which used fresh MSCs.
=== EC 2.6.99: Transferring Other Nitrogenous Groups === EC 2.6.99.1: dATP(dGTP)—DNA purinetransferase EC 2.6.99.2: pyridoxine 5′-phosphate synthase EC 2.6.99.3: O-ureido-L-serine synthase EC 2.6.99.4: Now EC 2.3.1.234, N6-L-threonylcarbamoyladenine synthase.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.